請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77769完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳慧文 | |
| dc.contributor.author | You-Ting Chen | en |
| dc.contributor.author | 陳宥廷 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:34:30Z | - |
| dc.date.available | 2020-08-08 | |
| dc.date.copyright | 2018-08-08 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-07-24 | |
| dc.identifier.citation | Albertini, A.A.V., Baquero, E., Ferlin, A., Gaudin, Y., 2012. Molecular and cellular aspects of rhabdovirus entry. Viruses 4, 117.
Amorim, M.J., Bruce, E.A., Read, E.K., Foeglein, A., Mahen, R., Stuart, A.D., Digard, P., 2011. A Rab11- and microtubule-dependent mechanism for cytoplasmic transport of influenza A virus viral RNA. J Virol 85, 4143-4156. Belouzard, S., Millet, J.K., Licitra, B.N., Whittaker, G.R., 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4, 1011. Bimbo, L.M., Denisova, O.V., Mäkilä, E., Kaasalainen, M., De Brabander, J.K., Hirvonen, J., Salonen, J., Kakkola, L., Kainov, D., Santos, H.A., 2013. Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano 7, 6884-6893. Bouvier, N.M., Palese, P., 2008. The biology of influenza viruses. Vaccine 26, D49-D53. Bowman, E.J., Siebers, A., Altendorf, K., 1988. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proceedings of the National Academy of Sciences of the United States of America 85, 7972-7976. Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., Adams, D.J., Xavier, R.J., Farzan, M., Elledge, S.J., 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139, 1243-1254. Burgui, I., Aragon, T., Ortin, J., Nieto, A., 2003. PABP1 and eIF4GI associate with influenza virus NS1 protein in viral mRNA translation initiation complexes. The Journal of general virology 84, 3263-3274. Cagno, V., Andreozzi, P., D’Alicarnasso, M., Jacob Silva, P., Mueller, M., Galloux, M., Le Goffic, R., Jones, S.T., Vallino, M., Hodek, J., Weber, J., Sen, S., Janeček, E.-R., Bekdemir, A., Sanavio, B., Martinelli, C., Donalisio, M., Rameix Welti, M.-A., Eleouet, J.-F., Han, Y., Kaiser, L., Vukovic, L., Tapparel, C., Král, P., Krol, S., Lembo, D., Stellacci, F., 2017. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nature Materials 17, 195. Cao, S., Liu, X., Yu, M., Li, J., Jia, X., Bi, Y., Sun, L., Gao, G.F., Liu, W., 2012. A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication. J Virol 86, 4883-4891. Cascone, M.G., Lazzeri, L., Carmignani, C., Zhu, Z., 2002. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. Journal of materials science. Materials in medicine 13, 523-526. Chen, H.-W., Cheng, J.X., Liu, M.-T., King, K., Peng, J.-Y., Zhang, X.-Q., Wang, C.-H., Shresta, S., Schooley, R.T., Liu, Y.-T., 2013. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Research 99, 371-382. Chen, H.W., Fang, Z.S., Chen, Y.T., Chen, Y.I., Yao, B.Y., Cheng, J.Y., Chien, C.Y., Chang, Y.C., Hu, C.J., 2017. Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection. ACS Appl Mater Interfaces 9, 39953-39961. Chiang, C., Beljanski, V., Yin, K., Olagnier, D., Ben Yebdri, F., Steel, C., Goulet, M.L., DeFilippis, V.R., Streblow, D.N., Haddad, E.K., Trautmann, L., Ross, T., Lin, R., Hiscott, J., 2015. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol 89, 8011-8025. Chin, C.R., Brass, A.L., 2013. A genome wide RNA interference screening method to identify host factors that modulate Influenza A virus replication. Methods 59, 217-224. Chrispal, A., 2012. Cleistanthus collinus poisoning. Journal of Emergencies, Trauma, and Shock 5, 160-166. Cox, N.J., Subbarao, K., 2000. Global epidemiology of influenza: past and present. Annual Review of Medicine 51, 407-421. Damascelli, B., Patelli, G.L., Lanocita, R., Di Tolla, G., Frigerio, L.F., Marchiano, A., Garbagnati, F., Spreafico, C., Ticha, V., Gladin, C.R., Palazzi, M., Crippa, F., Oldini, C., Calo, S., Bonaccorsi, A., Mattavelli, F., Costa, L., Mariani, L., Cantu, G., 2003. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR. American journal of roentgenology 181, 253-260. Davies, W.L., Grunert, R.R., Haff, R.F., McGahen, J.W., Neumayer, E.M., Paulshock, M., Watts, J.C., Wood, T.R., Hermann, E.C., Hoffmann, C.E., 1964. Antiviral activity of 1-adamantanamine (amantadine). Science (New York, N.Y.) 144, 862-863. De Clercq, E., 2006. Antiviral agents active against influenza A viruses. Nature reviews. Drug discovery 5, 1015-1025. De Jong, W.H., Borm, P.J.A., 2008. Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine 3, 133-149. Dias, A., Bouvier, D., Crepin, T., McCarthy, A.A., Hart, D.J., Baudin, F., Cusack, S., Ruigrok, R.W., 2009. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458, 914-918. Domingues, P., Golebiowski, F., Tatham, M.H., Lopes, A.M., Taggart, A., Hay, R.T., Hale, B.G., 2015. Global reprogramming of host SUMOylation during influenza virus infection. Cell reports 13, 1467-1480. Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., He, H., 2015. Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PloS one 10, e0119115. dos Santos Giuberti, C., de Oliveira Reis, E.C., Ribeiro Rocha, T.G., Leite, E.A., Lacerda, R.G., Ramaldes, G.A., de Oliveira, M.C., 2011. Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin. Journal of liposome research 21, 60-69. Drose, S., Bindseil, K.U., Bowman, E.J., Siebers, A., Zeeck, A., Altendorf, K., 1993. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry 32, 3902-3906. Dyer, A.M., Hinchcliffe, M., Watts, P., Castile, J., Jabbal-Gill, I., Nankervis, R., Smith, A., Illum, L., 2002. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharmaceutical research 19, 998-1008. Eisfeld, A.J., Neumann, G., Kawaoka, Y., 2011. Human immunodeficiency virus rev-binding protein is essential for influenza a virus replication and promotes genome trafficking in late-stage infection. J Virol 85, 9588-9598. Fass, E., Shvets, E., Degani, I., Hirschberg, K., Elazar, Z., 2006. Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. The Journal of biological chemistry 281, 36303-36316. Francis, T., Jr., 1940. A new type of virus from epidemic influenza. Science (New York, N.Y.) 92, 405-408. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research 100, 10.1016/j.antiviral.2013.1009.1015. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K., 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial agents and chemotherapy 46, 977-981. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H.N., Chen, J., 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proceedings of the National Academy of Sciences of the United States of America 101, 8676-8681. Guo, J., Gao, X., Su, L., Xia, H., Gu, G., Pang, Z., Jiang, X., Yao, L., Chen, J., Chen, H., 2011. Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32, 8010-8020. Han, Q., Chang, C., Li, L., Klenk, C., Cheng, J., Chen, Y., Xia, N., Shu, Y., Chen, Z., Gabriel, G., Sun, B., Xu, K., 2014. Sumoylation of influenza A virus nucleoprotein is essential for intracellular trafficking and virus growth. Journal of Virology 88, 9379-9390. Harvie, P., Omar, R.F., Dusserre, N., Desormeaux, A., Gourde, P., Tremblay, M., Beauchamp, D., Bergeron, M.G., 1996. Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 12, 451-461. Herlocher, M.L., Truscon, R., Elias, S., Yen, H.L., Roberts, N.A., Ohmit, S.E., Monto, A.S., 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. The Journal of infectious diseases 190, 1627-1630. Holm, C.K., Rahbek, S.H., Gad, H.H., Bak, R.O., Jakobsen, M.R., Jiang, Z., Hansen, A.L., Jensen, S.K., Sun, C., Thomsen, M.K., Laustsen, A., Nielsen, C.G., Severinsen, K., Xiong, Y., Burdette, D.L., Hornung, V., Lebbink, R.J., Duch, M., Fitzgerald, K.A., Bahrami, S., Mikkelsen, J.G., Hartmann, R., Paludan, S.R., 2016. Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses. Nature Communications 7, 10680. Hu, C.-M.J., Chang, W.-S., Fang, Z.-S., Chen, Y.-T., Wang, W.-L., Tsai, H.-H., Chueh, L.-L., Takano, T., Hohdatsu, T., Chen, H.-W., 2017. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Scientific Reports 7, 13043. Hurt, A.C., Holien, J.K., Parker, M.W., Barr, I.G., 2009. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 69, 2523-2531. Huss, M., Wieczorek, H., 2009. Inhibitors of V-ATPases: old and new players. The Journal of experimental biology 212, 341-346. Isomura, S., Ichikawa, T., Miyazu, M., Naruse, H., Shibata, M., Imanishi, J., Matsuo, A., Kishida, T., Karaki, T., 1982. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken journal 25, 131-137. Iwatsuki-Horimoto, K., Horimoto, T., Fujii, Y., Kawaoka, Y., 2004. Generation of influenza A virus NS2 (NEP) mutants with an altered nuclear export signal sequence. Journal of Virology 78, 10149-10155. König, R., Stertz, S., Zhou, Y., Inoue, A., Hoffmann, H.H., Bhattacharyya, S., Alamares, J.G., Tscherne, D.M., Ortigoza, M.B., Liang, Y., Gao, Q., Andrews, S.E., Bandyopadhyay, S., Jesus, P.D., Tu, B.P., Pache, L., Shih, C., Orth, A., Bonamy, G., Miraglia, L., Ideker, T., García-Sastre, A., Young, J.A.T., Palese, P., Shaw, M.L., Chanda, S.K., 2010. Human host factors required for influenza virus replication. Nature 463, 813-817. Kilbourne, E.D., 2006. Influenza pandemics of the 20th century. Emerging Infectious Diseases 12, 9-14. Leser, G.P., Lamb, R.A., 2005. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 342, 215-227. Li, L.Q., Xie, W.J., Pan, D., Chen, H., Zhang, L., 2016a. Inhibition of autophagy by bafilomycin A1 promotes chemosensitivity of gastric cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37, 653-659. Li, S.W., Yang, T.C., Lai, C.C., Huang, S.H., Liao, J.M., Wan, L., Lin, Y.J., Lin, C.W., 2014. Antiviral activity of aloe-emodin against influenza A virus via galectin-3 up-regulation. European journal of pharmacology 738, 125-132. Li, Y., Lin, Z., Zhao, M., Xu, T., Wang, C., Hua, L., Wang, H., Xia, H., Zhu, B., 2016b. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways. ACS Applied Materials & Interfaces 8, 24385-24393. Lin, C.J., Lin, H.J., Chen, T.H., Hsu, Y.A., Liu, C.S., Hwang, G.Y., Wan, L., 2015. Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PloS one 10, e0117602. Locatelli, E., Comes Franchini, M., 2012. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. Journal of Nanoparticle Research 14, 1316. Müller, K.H., Kainov, D.E., El Bakkouri, K., Saelens, X., De Brabander, J.K., Kittel, C., Samm, E., Muller, C.P., 2011. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. British Journal of Pharmacology 164, 344-357. Malakhov, M.P., Aschenbrenner, L.M., Smee, D.F., Wandersee, M.K., Sidwell, R.W., Gubareva, L.V., Mishin, V.P., Hayden, F.G., Kim, D.H., Ing, A., Campbell, E.R., Yu, M., Fang, F., 2006. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial agents and chemotherapy 50, 1470-1479. Matrosovich, M.N., Matrosovich, T.Y., Gray, T., Roberts, N.A., Klenk, H.D., 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78, 12665-12667. Matsuoka, Y., Matsumae, H., Katoh, M., Eisfeld, A.J., Neumann, G., Hase, T., Ghosh, S., Shoemaker, J.E., Lopes, T.J.S., Watanabe, T., Watanabe, S., Fukuyama, S., Kitano, H., Kawaoka, Y., 2013. A comprehensive map of the influenza A virus replication cycle. BMC Systems Biology 7, 97-97. Mauvezin, C., Neufeld, T.P., 2015. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy 11, 1437-1438. McCauley, J.W., Mahy, B.W., 1983. Structure and function of the influenza virus genome. Biochemical Journal 211, 281-294. Mousavi, S.A., Kjeken, R., Berg, T.O., Seglen, P.O., Berg, T., Brech, A., 2001. Effects of inhibitors of the vacuolar proton pump on hepatic heterophagy and autophagy. Biochimica et Biophysica Acta (BBA) - Biomembranes 1510, 243-257. Mu, L., Feng, S.S., 2002. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). Journal of Controlled Release 80, 129-144. Niikura, K., 2006. Vacuolar ATPase as a drug discovery target. Drug news & perspectives 19, 139-144. Noda, T., Sagara, H., Yen, A., Takada, A., Kida, H., Cheng, R.H., Kawaoka, Y., 2006. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 439, 490. O'Neill, R.E., Talon, J., Palese, P., 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. The EMBO Journal 17, 288-296. Ochiai, H., Sakai, S., Hirabayashi, T., Shimizu, Y., Terasawa, K., 1995. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res 27, 425-430. Okigawa, M., Maeda, T., Kawano, N., 1970. The isolation and structure of three new lignans from Justicia procumbens Linn. var. leucantha honda. Tetrahedron 26, 4301-4305. Paciotti, G.F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R.E., Tamarkin, L., 2004. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug delivery 11, 169-183. Panyam, J., Zhou, W.Z., Prabha, S., Sahoo, S.K., Labhasetwar, V., 2002. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16, 1217-1226. Pierson, T.C., Diamond, M.S., 2012. Degrees of maturity: the complex structure and biology of flaviviruses. Current opinion in virology 2, 168-175. Portsmouth, S., Kawaguchi, K., Arai, M., Tsuchiya, K., Uehara, T., 2017. Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza. Open Forum Infectious Diseases 4, S734-S734. Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent endpoints. American Journal of Epidemiology 27, 493-497. Rossman, J.S., Lamb, R.A., 2011. Influenza virus assembly and budding. Virology 411, 229-236. Shi, D.K., Zhang, W., Ding, N., Li, M., Li, Y.X., 2012. Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors. European journal of medicinal chemistry 47, 424-431. Sieczkarski, S.B., Whittaker, G.R., 2003. Differential requirements of Rab5 and Rab7 for endocytosis of influenza and other enveloped viruses. Traffic (Copenhagen, Denmark) 4, 333-343. Sillman, B., Bade, A.N., Dash, P.K., Bhargavan, B., Kocher, T., Mathews, S., Su, H., Kanmogne, G.D., Poluektova, L.Y., Gorantla, S., McMillan, J., Gautam, N., Alnouti, Y., Edagwa, B., Gendelman, H.E., 2018. Creation of a long-acting nanoformulated dolutegravir. Nature Communications 9, 443. Smith, C.B., Charette, R.P., Fox, J.P., Cooney, M.K., Hall, C.E., 1980. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. The Journal of infectious diseases 141, 548-554. Smith, W., Andrewes, C.H., Laidlaw, P.P., 1933. A virus obtained from influenza patients. The Lancet 222, 66-68. Sorensen, M.G., Henriksen, K., Neutzsky-Wulff, A.V., Dziegiel, M.H., Karsdal, M.A., 2007. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 22, 1640-1648. Sun, E., He, J., Zhuang, X., 2013. Dissecting the role of COPI complexes in influenza virus infection. J Virol 87, 2673-2685. Suzuki, T., Yamaya, M., Sekizawa, K., Hosoda, M., Yamada, N., Ishizuka, S., Nakayama, K., Yanai, M., Numazaki, Y., Sasaki, H., 2001. Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. American journal of physiology. Lung cellular and molecular physiology 280, L1115-1127. Taubenberger, J.K., 2006. The origin and virulence of the 1918 “Spanish” influenza Virus. Proceedings of the American Philosophical Society 150, 86-112. Townsley, A.C., Weisberg, A.S., Wagenaar, T.R., Moss, B., 2006. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol 80, 8899-8908. Tuvim, M.J., Gilbert, B.E., Dickey, B.F., Evans, S.E., 2012. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PloS one 7, e30596. Wang, N.X., Zheng, J.J., 2009. Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein science : a publication of the Protein Society 18, 707-715. Wang, W., Wu, J., Zhang, X., Hao, C., Zhao, X., Jiao, G., Shan, X., Tai, W., Yu, G., 2017. Inhibition of influenza A virus infection by fucoidan targeting viral neuraminidase and cellular EGFR pathway. Scientific Reports 7, 40760. Ward, C.L., Dempsey, M.H., Ring, C.J., Kempson, R.E., Zhang, L., Gor, D., Snowden, B.W., Tisdale, M., 2004. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 29, 179-188. Wilczewska, A.Z., Niemirowicz, K., Markiewicz, K.H., Car, H., 2012. Nanoparticles as drug delivery systems. Pharmacological Reports 64, 1020-1037. Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., James, J., Air, G.M., Capra, J.D., Ahmed, R., Wilson, P.C., 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667. Wu, C.Y., Jeng, K.S., Lai, M.M., 2011. The SUMOylation of matrix protein M1 modulates the assembly and morphogenesis of influenza A virus. J Virol 85, 6618-6628. Wu, Y.C., Wu, W.K.K., Li, Y., Yu, L., Li, Z.J., Wong, C.C.M., Li, H.T., Sung, J.J.Y., Cho, C.H., 2009. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochemical and Biophysical Research Communications 382, 451-456. Yamamoto, A., Tagawa, Y., Yoshimori, T., Moriyama, Y., Masaki, R., Tashiro, Y., 1998. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell structure and function 23, 33-42. Yan, Y., Jiang, K., Liu, P., Zhang, X., Dong, X., Gao, J., Liu, Q., Barr, M.P., Zhang, Q., Hou, X., Meng, S., Gong, P., 2016. Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways. Scientific Reports 6, 37052. Yang, A., Yang, L., Liu, W., Li, Z., Xu, H., Yang, X., 2007. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vitro evaluation. International Journal of Pharmaceutics 331, 123-132. Yanguez, E., Castello, A., Welnowska, E., Carrasco, L., Goodfellow, I., Nieto, A., 2011. Functional impairment of eIF4A and eIF4G factors correlates with inhibition of influenza virus mRNA translation. Virology 413, 93-102. Yanguez, E., Rodriguez, P., Goodfellow, I., Nieto, A., 2012. Influenza virus polymerase confers independence of the cellular cap-binding factor eIF4E for viral mRNA translation. Virology 422, 297-307. Zhao, Y., Ni, C., Zhang, Y., Zhu, L., 2012. Synthesis and bioevaluation of diphyllin glycosides as novel anticancer agents. Archiv der Pharmazie 345, 622-628. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77769 | - |
| dc.description.abstract | 流感病毒每年在全球造成許多發病、重症及死亡，是全球相當關心的公共衛生議題，傳統的治療策略為使用拮抗病毒蛋白質的藥物，然而帶有抗藥性突變的流感病毒毒株的出現，成為臨床治療上一大挑戰。Diphyllin與Bafilomycin是強效的Vacuolar ATPase阻斷劑，先前被證實對流感病毒具有抑制效果，然而，它們極差的水溶性和可能的副作用限制了它們的臨床應用。此研究的核心目標即是設計新穎的抗流感病毒治療策略，利用奈米顆粒來裝載與遞送抗病毒藥物，以提高藥物的安全性與效性。本研究中，我們分別製備了裝載Diphyllin和Bafilomycin的奈米顆粒，以動態光散射儀與穿透性電子顯微鏡觀察奈米顆粒的型態、粒徑與表面電位，並以高效液相色譜分析藥物在奈米顆粒中的包覆率。實驗結果顯示，我們所製備的奈米顆粒能有效地遞送進入Fcwf-4、ARPE-19、MH-S等多種細胞內部，並緩慢的釋放。在MDCK及MH-S細胞中顯示，以奈米顆粒包覆遞送之藥物比未包覆之藥物具有較低的細胞毒性，與顯著較高的抗流感病毒活性。在活體的安全性研究中，分別由靜脈內及鼻腔內給予小鼠Diphyllin奈米顆粒，觀測其體重變化及血液生化參數，發現小鼠對於Diphyllin奈米顆粒有良好的耐受性，並在流感病毒攻毒之後，有給予Diphyllin奈米顆粒之組別與未給藥組相比，有較少的體重減輕。另一方面，我們也製備了外覆紅血球膜的奈米顆粒，透過紅血球膜與流感病毒的交互作用，此奈米顆粒能夠專一地被流感病毒感染後的細胞攝入，有機會發展為標靶治療藥物之平台。總結來說，本研究顯示以奈米載體遞送抗病毒藥物為一新穎、有潛力之治療策略，能夠對病毒傳染病之藥物發展帶來更多希望。 | zh_TW |
| dc.description.abstract | Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide. Conventional treatments against the disease are designed to target viral proteins. Nevertheless, the emergence of new influenza viral strains carrying drug-resistant mutations that can outpace the development of pathogen-targeting antivirals presents a major clinical challenge. Diphyllin and bafilomycin are potent vacuolar ATPase inhibitors, and previously known to have anti-influenza virus activity. However, their poor water solubility and potential off-target effect may limit the clinical application. The central objective of this project is to generate a novel anti-influenza therapeutic strategy, integrating nanoparticle technology to enhance host-targeting antiviral delivery towards improved drug safety and efficacy. In this study, we successfully constructed diphyllin-loaded nanoparticles and bafilomycin-loaded nanoparticles. The shape, size, and zeta potential of these nanoparticles were measured by dynamic light scattering and transmission electron microscopy, and the drug encapsulation was analyzed by high-performance liquid chromatography. The nanoparticles can be efficiently delivered intracellularly to multiple cell lines including Fcwf-4, ARPE-19, and MH-S cells. Moreover, the drug-loaded nanoparticles have a sustained drug release profile. The nanoformulated drugs exhibited lower cytotoxicity as compared to the free drug formulation in MDCK and MH-S cells. Furthermore, drug-loaded nanoparticles demonstrated prominent broad-spectrum anti-influenza activity in vitro. In an in vivo safety study that evaluated body weight and blood chemistry parameters following intravenous or intranasal administration, diphyllin nanoparticles were well-tolerated in mice. Furthermore, after infection, the mice treated with diphyllin-loaded nanoparticles had less body weight loss as compared to the control group. In addition, to further improve targeting delivery of nanoparticles to virus-infected cells, fluorescent nanoparticles were coated with the red blood cell membrane to validate the viral infection-specific targeting of nanoparticles. Collectively, this work highlights nanoformulated vacuolar ATPase inhibitors as potential host-targeted treatments against influenza. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:34:30Z (GMT). No. of bitstreams: 1 ntu-107-R05629009-1.pdf: 2340270 bytes, checksum: fe0c164e7c3c4648422ca5ed91faa7bb (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | Contents
中文摘要 I Abstract III List of figures IX List of tables XI Chapter 1 Introduction 1 1.1 Background and epidemiology of influenza virus 1 1.2 Influenza virus replication 2 1.3 Treatment of influenza virus infection 5 1.4 Vacuolar ATPase (V-ATPase) and its inhibitors 6 1.5 Application of diphyllin 8 1.6 Application of bafilomycin 8 1.7 Nanoparticulate drug delivery systems 10 1.8 The objective of this study 11 Chapter 2 Materials and methods 13 2.1 Cells and viruses 13 2.2 Preparation of diphyllin-loaded nanoparticles 14 2.3 Preparation of bafilomycin-loaded nanoparticles 15 2.4 Preparation of DiD-load nanoparticles 15 2.5 Preparation of RBC membrane-coated DiD-loaded nanoparticles 16 2.6 Transmission electron microscopy (TEM) and dynamic light scattering (DLS) 17 2.7 High-performance liquid chromatography (HPLC) 18 2.8 Drug release studies 18 2.9 Cellular uptake studies 19 2.10 Cytotoxicity evaluation of free drugs and drug-loaded nanoparticles in vitro 19 2.11 Assessment of the half inhibitory concentration (IC50) in vitro 20 2.12 Assessment of antiviral activity 20 2.13 Virus titration 21 2.13.1 Hemagglutination assay (HA assay) 21 2.13.2 50% of Tissue Culture Infective Dose (TCID50) 21 2.13.3 Plaque assay 22 2.13.4 Plasmid construction and quantitative PCR (qPCR) of influenza virus 23 2.14 In vivo tolerance of diphyllin nanoparticles 25 2.15 Establishment of animal models of influenza virus challenge 25 2.16 Evaluation of antiviral efficacy of diphylliny nanoparticles in vivo 26 2.17 Targeted delivery to virus-infected cells by RBC membrane-coated nanoparticles 26 2.18 Ethics statement 27 2.19 Statistical analyses 28 Chapter 3 Results 29 3.1 Characterization of diphyllin-loaded nanoparticles 29 3.2 Characterization of bafilomycin-loaded nanoparticles 29 3.3 Characterization of DiD-load nanoparticles 30 3.4 Characterization of RBC membrane-coated Did-loaded nanoparticles 31 3.5 Release kinetics of drug-loaded nanoparticles 31 3.6 Assessment of cellular uptake of nanoparticles 32 3.7 CC50 of free drugs and drug-loaded nanoparticles 32 3.8 IC50 of free drug and drug-loaded nanoparticles 33 3.9 Antiviral activity of diphyllin-loaded nanoparticles 34 3.10 Antiviral activity of bafilomycin-loaded nanoparticles 34 3.11 Toxicology of diphyllin nanoparticles in vivo 35 3.12 Establishment of 50% mice lethal dose of influenza virus (H1N1) and determination of viral titer in the lung, trachea, and BAL 36 3.13 Antiviral efficacy of diphylliny nanoparticles in vivo 36 3.14 Targeted delivery to virus-infected cells by RBC membrane coated-nanoparticles 37 Chapter 4 Discussion 38 Chapter 5 Figures and tables 45 Chapter 6 References 72 | |
| dc.language.iso | en | |
| dc.subject | Bafilomycin | zh_TW |
| dc.subject | 奈米顆粒 | zh_TW |
| dc.subject | Diphyllin | zh_TW |
| dc.subject | Vacuolar ATPase 阻斷劑 | zh_TW |
| dc.subject | 流感病毒 | zh_TW |
| dc.subject | Influenza virus | en |
| dc.subject | Vacuolar ATPase inhibitor | en |
| dc.subject | Diphyllin | en |
| dc.subject | Bafilomycin | en |
| dc.subject | Nanoparticles | en |
| dc.title | 以裝載Vacuolar ATPase 阻斷劑之奈米顆粒用於抗流
感病毒感染之效果 | zh_TW |
| dc.title | Antiviral Efficacy of the Nanoparticulate Vacuolar
ATPase Blockers against Influenza Virus Infection | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 胡哲銘 | |
| dc.contributor.oralexamcommittee | 陳怡寧,徐維莉,王金和 | |
| dc.subject.keyword | 流感病毒,Vacuolar ATPase 阻斷劑,Diphyllin,Bafilomycin,奈米顆粒, | zh_TW |
| dc.subject.keyword | Influenza virus,Vacuolar ATPase inhibitor,Diphyllin,Bafilomycin,Nanoparticles, | en |
| dc.relation.page | 80 | |
| dc.identifier.doi | 10.6342/NTU201801911 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-07-25 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-R05629009-1.pdf 未授權公開取用 | 2.29 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。